Evidence map›Paper›PMID 25356020›Full record

ReviewWorld journal of gastroenterology2014

Hepatitis B virus and hepatitis C virus dual infection.

Gaia Caccamo, Francesca Saffioti, Giovanni Raimondo

Open access · hybridAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 123 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. [Mechanism and clinical significance of HBV reactivation after anti-HCV therapy].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Management of hepatitis B and C in special population.World journal of gastroenterology · 2021
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Gaia CaccamoGaia Caccamo, Francesca Saffioti, Giovanni Raimondo, Division of Clinical and Molecular Hepatology, Department of Internal Medicine, University Hospital of Messina, 98124 Messina, Italy.
Francesca SaffiotiGaia Caccamo, Francesca Saffioti, Giovanni Raimondo, Division of Clinical and Molecular Hepatology, Department of Internal Medicine, University Hospital of Messina, 98124 Messina, Italy.
Giovanni RaimondoGaia Caccamo, Francesca Saffioti, Giovanni Raimondo, Division of Clinical and Molecular Hepatology, Department of Internal Medicine, University Hospital of Messina, 98124 Messina, Italy.
University of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) share common mode of transmission and both are able to induce a chronic infection. Dual HBV/HCV chronic coinfection is a fairly frequent occurrence, especially in high endemic areas and among individuals at high risk of parenterally transmitted infections. The intracellular interplay between HBV and HCV has not yet been sufficiently clarified, also due to the lack of a proper in vitro cellular model. Longitudinal evaluation of serum HBV DNA and HCV RNA amounts has revealed that complex virological profiles may be present in coinfected patients. Dual HBV/HCV infection has been associated to a severe course of the liver disease and to a high risk of developing hepatocellular carcinoma. Despite the clinical importance, solid evidence and clear guidelines for treatment of this special population are still lacking. This review summarizes the available data on the virological and clinical features as well as the therapeutic options of the dual HBV/HCV infection, and highlights the aspects that need to be better clarified.

Indexed as

CoinfectionAntiviral AgentsCarcinoma, HepatocellularDisease ProgressionHepacivirusHepatitis B, ChronicHepatitis B virusHepatitis C, ChronicHost-Pathogen InteractionsHumansLiver NeoplasmsRisk AssessmentRisk FactorsAntiviral AgentsAntiviral therapyChronic hepatitisCirrhosisHepatitis B virus/hepatitis C virus coinfectionHepatocellular carcinomaViral interaction

Identifiers

PMID25356020
PMCPMC4209523
OpenAlexW2064698907

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.